secwatch.observer — SEC 8-K summary
======================================

Issuer:     Evoke Pharma Inc (—)
CIK:        0001403708
Form:       8-K
Filed at:   2024-10-22T23:59:59+00:00
Accession:  0000950170-24-116111
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Evoke Pharma appoints Benjamin Smeal as Class II director
---------------------------------------------------------

- Board appoints Benjamin Smeal as Class II director effective October 18, 2024, with term expiring at 2027 annual meeting.
- Smeal is a private investor; previously Associate Director at Willett Advisors (Michael Bloomberg's family office) and Senior Investment Analyst at Kenmare Management.
- Appointment made pursuant to nominating rights in letter agreement with Nantahala Capital Management dated September 27, 2024.
- Granted options to purchase 5,833 shares vesting in equal annual installments over three years; will receive cash compensation per non-employee director compensation program.
- Smeal also appointed to Audit, Compensation, and Nominating and Corporate Governance Committees; Board determined independent per Nasdaq rules.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1403708/000095017024116111/0000950170-24-116111-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1403708/000095017024116111/evok-20241018.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-116111

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer